AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8758538
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose dexamethasone‐alpha Interferon
Trial: 29980851
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein concentrate (0.33 g·kg BM‐1)
Trial: 29980851
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein concentrate (0.33 g·kg BM‐1) with prior aerobic exercise
Trial: 29980851
Drug: Control (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (75 g oral glucose tolerance test)
Trial: 20443797
Drug: Conical neck
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conical neck design implant (C)
Trial: 20443797
Drug: Straight shape
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Straight shape implant (S)
Trial: 12352800
Drug: CRM(197) pneumococcal
RxNorm normalized name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8
DrugBank: Streptococcus pneumoniae type 8 capsular polysaccharide antigen (DB10326)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRM(197) pneumococcal conjugate vaccine (PCV)
Trial: 12352800
Drug: Meningococcal type
RxNorm normalized name: MENINGOCOCCAL B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meningococcal type C CRM(197) conjugate vaccine
Trial: 7754005
Drug: Transcatheter arterial
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcatheter arterial embolization (TAE) with gelatin sponge (GS) containing anticancer agents (protocol 1)
Trial: 7754005
Drug: Transcatheter arterial
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcatheter arterial embolization (TAE) with GS and iodized oil mixed with anticancer agents (protocol 2)
Trial: 7754005
Drug: Transcatheter arterial
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcatheter arterial embolization (TAE) with iodized oil with anticancer agents (protocol 3)
Trial: 2186321
Drug: CHOEP (cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHOEP (cyclophosphamide 750 mg/m2 i.v. day 1, doxorubicin 50 mg/m2 i.v. day 1, vincristine 2 mg i.v. day 1, etoposide 100 mg/m2 i.v. days 3-5, prednisolone 100 mg p.o. days 1-5)
Trial: 2186321
Drug: hCHOP alternating
RxNorm normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hCHOP alternating with IVEP (cyclophosphamide 1,200 mg/m2 i.v. day 1, doxorubicin 40 mg/m2 i.v. days 1 + 2, vincristine 2 mg i.v. day 1, prednisolone 100 mg p.o. days 1-5)
Trial: 31153358
Drug: Scalp nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scalp nerve block (SNB) with 15 mL of 0.75% ropivacaine
Trial: 31153358
Drug: Local anesthetic
RxNorm normalized name: Local anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthetic infiltration (LA) with 15 mL of 0.75% ropivacaine
Trial: 31153358
Drug: Routine intravenous
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine intravenous analgesia (Control group)
Trial: 28636855
Drug: RIV4 (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RIV4 (45 μg of recombinant hemagglutinin [HA] per strain, 180 μg of protein per dose)
Trial: 28636855
Drug: IIV4 (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IIV4 (15 μg of HA per strain, 60 μg of protein per dose)
Trial: 20627917
Drug: Automatic positive
RxNorm normalized name: AMMONIA,AROMATIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automatic positive airway pressure (APAP) titration
Trial: 24163991
Drug: Polysomnography manual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polysomnography manual titration
Trial: 8156653
Drug: Metoclopramide 20
RxNorm normalized name: metoclopramide 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 20 mg (0.2-0.3 mg/kg)
Trial: 8156653
Drug: Prochlorperazine 12.5
RxNorm normalized name: prochlorperazine 12.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prochlorperazine 12.5 mg (0.1-0.2 mg/kg)
Trial: 3131791
Drug: Alcohol (0.695
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (0.695 g/kg)
Trial: 31690107
Drug: 3 months
RxNorm normalized name: TABLET, DOSE PACK, 3 MONTHS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 months of directly observed once-weekly rifapentine plus isoniazid
Trial: 31690107
Drug: 9 months
RxNorm normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 9 months of self-administered daily isoniazid
Trial: 23231878
Drug: Culturally adapted
RxNorm normalized name: casein, emmental cultured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culturally adapted cognitive behavioural therapy for psychosis (CaCBTp)
Trial: 21209123
Drug: ADA160/80 (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADA160/80 (160 mg at week 0, 80 mg at week 2, 40 mg at weeks 4 and 6)
Trial: 21209123
Drug: ADA80/40 (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADA80/40 (80 mg at week 0, 40 mg at weeks 2, 4 and 6)
Trial: 17033926
Drug: CMF chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMF chemotherapy plus tamoxifen for 1 year
Trial: 17033926
Drug: CMF chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMF chemotherapy for 1 year
Trial: 9573748
Drug: Estrogens alone
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogens alone administered transdermically (17 beta‐estradiol, 50 micrograms/day)
Trial: 9573748
Drug: Transdermic estrogens
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermic estrogens plus oral progestagen (17 beta‐estradiol 50 micrograms/day, acetate medroxyprogestogen 10 mg/day for 12 days per month)
Trial: 9573748
Drug: Oral conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral conjugated equine estrogens (0.625 mg/day) plus oral progestagen (10 mg/day for 12 days per month)
Trial: 20470802
Drug: Anti-TNF treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-TNF treatment plus DMARDs
Trial: 15821690
Drug: Functional appliances
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional appliances (Fränkel II or Herbst); average treatment duration to final cephalograms: 35.8 months
Trial: 15821690
Drug: Bilateral sagittal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral sagittal split ramus osteotomy; average treatment duration to final cephalograms: 34.9 months
Trial: 12388961
Drug: Dinoprostone gel
RxNorm normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dinoprostone gel 5 mg intracervically, with repeated dosing one time 6 hours later
Trial: 7588670
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium 100 mg suppositories
Trial: 2105670
Drug: Glycerol-based peripheral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycerol-based peripheral hyperalimentation solution (after eliminating in-line filters)
Trial: 477550
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of theophylline, diprophylline, and proxyphylline
Trial: 31870451
Drug: Physiotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiotherapy with protein-rich nutritional supplement plus anabolic steroid
Trial: 31870451
Drug: Physiotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiotherapy with protein-rich nutritional supplement plus placebo
Trial: 28291238
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg escitalopram (ESC)
Trial: 2682593
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg amitriptyline (AMI)
Trial: 22023735
Drug: Oral testosterone
RxNorm normalized name: testosterone Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral testosterone undecanoate and high calorie oral nutritional supplement
Trial: 22023735
Drug: Placebo medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo medication and low calorie oral nutritional supplementation
Trial: 23621805
Drug: Individual music
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual music therapy for 6 weeks
Trial: 19132197
Drug: Clopidogrel 75
RxNorm normalized name: clopidogrel 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 75 mg/day for 10 days
Trial: 19132197
Drug: Clopidogrel 300
RxNorm normalized name: clopidogrel 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 300 mg on day 11
Trial: 17324742
Drug: L-NMMA (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NMMA (3 mg/kg intravenously)
Trial: 15002070
Drug: Pentoxifylline (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (10 mg/kg)
Trial: 11277274
Drug: Pamidronate (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate (90 mg single-dose infusion)
Trial: 8083102
Drug: lonidamine +
RxNorm normalized name: lonidamine
DrugBank: Lonidamine (DB06266)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lonidamine + radiation therapy
Trial: 8083102
Drug: placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo + radiation therapy
Trial: 2536765
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg fluoxetine
Trial: 338109
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg PGE2 in 2% gel
Trial: 338109
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg PGE2 in 4% gel
Trial: 24887490
Drug: Group 1:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1: 20 mg/day lutein and 2 mg/day zeaxanthin
Trial: 24887490
Drug: Group 2:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2: 10 mg/day meso-zeaxanthin, 10 mg/day lutein, and 2 mg/day zeaxanthin
Trial: 24887490
Drug: Group 3:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 3: 17 mg/day meso-zeaxanthin, 3 mg/day lutein, and 2 mg/day zeaxanthin
Trial: 9338554
Drug: Topical fluticasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical fluticasone propionate
Trial: 9338554
Drug: Topical glucocorticoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical glucocorticoid therapy
Trial: 29358446
Drug: Fast track
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast track initiation counselling for patients eligible for antiretroviral therapy (ART)
Trial: 29358446
Drug: Decentralised medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decentralised medication delivery for stable ART patients
Trial: 21076158
Drug: AAD treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AAD treatment for the first 6 weeks after ablation
Trial: 21076158
Drug: No AAD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No AAD treatment for the first 6 weeks after ablation
Trial: 18215983
Drug: Protease inhibitor
RxNorm normalized name: Protease inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protease inhibitor dose escalation in response to therapeutic drug monitoring (TDM) with an inhibitory quotient
Trial: 14614766
Drug: Leucocyte IFNalpha
RxNorm normalized name: Zenalpha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leucocyte IFNalpha 3MU three times weekly plus ribavirin
Trial: 2319467
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg nicotine gum
Trial: 11104110
Drug: 0 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg nicotine gum
Trial: 2319467
Drug: Higher doses
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher doses (2 mg and 4 mg)
Trial: 493904
Drug: Cool, dry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cool, dry room air (CDA) at 23 degrees C with 3 mg of water and 7.3 cal of heat content/l
Trial: 493904
Drug: Over-saturated air
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Over-saturated air (OSA) at room temperature containing 43 mg water and 16.3 cal/l
Trial: 493904
Drug: Warm, humidified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warm, humidified air (WHA) at 37 degrees C with 43 mg water and 34.7 cal/l
Trial: 493904
Drug: Hot, dry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hot, dry air (HDA) at 120 degrees C having 3 mg water and 24.4 cal/l
Trial: 31478892
Drug: Fentanyl (time-weighted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (time-weighted cumulative dose above the median)
Trial: 27926528
Drug: Ketamine (sub-anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (sub-anesthetic dose of racemic ketamine hydrochloride)
Trial: 25649801
Drug: High-dose B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose B vitamin therapy
Trial: 25649801
Drug: Low-dose B
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose B vitamin therapy
Trial: 23566636
Drug: Low eGFR
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low eGFR (<45 mL/min/1.73 m²)
Trial: 21627339
Drug: Bevacizumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (10 mg/kg) plus Interferon-α (9 MIU)
Trial: 21627339
Drug: Bevacizumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (10 mg/kg) plus Interferon-α (6 MIU)
Trial: 21627339
Drug: Bevacizumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (10 mg/kg) plus Interferon-α (3 MIU)
Trial: 21627339
Drug: Sunitinib (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib (50 mg)
Trial: 18042575
Drug: pegylated-interferon alpha
RxNorm normalized name: Pegylated interferon alpha-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pegylated-interferon alpha (PEG-2a) monotherapy
Trial: 11708311
Drug: Soybean oil-based
RxNorm normalized name: Soybean Oil
DrugBank: Soybean oil (DB09422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soybean oil-based preparation of CoQ10 (300 mg daily for 7 days)
Trial: 11708311
Drug: Complex micelle
RxNorm normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complex micelle emulsion of CoQ10 (300 mg daily for 7 days)
Trial: 11708311
Drug: Both preparations
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both preparations of CoQ10
Trial: 9149124
Drug: Carboplatin (CBDCA)
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin (CBDCA) administered 10 min after achieving target temperature (41.8 degrees C) during the plateau phase of WBH
Trial: 9149124
Drug: Carboplatin (CBDCA)
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin (CBDCA) administered on an early schedule before reaching target temperature
Trial: 22954645
Drug: Moderate dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate dose of alcohol
Trial: 25282112
Drug: Metformin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin treatment in PCOS women
Trial: 20514951
Drug: Gabapentin 1200
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin 1200 mg preoperatively, then 600 mg twice a day for two days postoperatively
Trial: 10799426
Drug: Salbutamol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (200 microg three times daily)
Trial: 25898343
Drug: Antidepressant Medication
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant Medication (ADM)
Trial: 10407233
Drug: Treatment exposure
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment exposure (dose)
Trial: 7770495
Drug: Multichannel functional
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multichannel functional electrical stimulation (MFES) followed by conventional therapy
Trial: 7770495
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy followed by multichannel functional electrical stimulation (MFES)
Trial: 31402112
Drug: No bowel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No bowel preparation (NBP)
Trial: 30058184
Drug: Outpatient multidisciplinary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient multidisciplinary therapy (36 weeks)
Trial: 24703170
Drug: Adjunctive tamoxifen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive tamoxifen
Trial: 16150764
Drug: Social behaviour
RxNorm normalized name: Safety 1st Social Safety Pack KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Social behaviour and network therapy
Trial: 8621843
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP) 200 micrograms daily
Trial: 25953940
Drug: 3% saline
RxNorm normalized name: dextrose 2.5%-0.3% saline (obsolete)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% saline compresses (Group A) 3 times weekly
Trial: 25953940
Drug: Mupirocine 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mupirocine 2% ointment (Group B) 3 times weekly
Trial: 25953940
Drug: No aseptic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No aseptic agents (Group C)
Trial: 17178976
Drug: Low-dose quadruple
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose quadruple antihypertensive combination (4 agents at one-quarter dosage; n=22)
Trial: 17178976
Drug: Amlodipine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (5 mg; n=22)
Trial: 17178976
Drug: Atenolol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (50 mg; n=20)
Trial: 17178976
Drug: Bendroflumethiazide (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendroflumethiazide (2.5 mg; n=22)
Trial: 17178976
Drug: Captopril (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (50 mg twice daily; n=22)
Trial: 17178976
Drug: Low-dose quadruple
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose quadruple antihypertensive combination
Trial: 17178976
Drug: Individual drugs
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual drugs (Amlodipine, Atenolol, Bendroflumethiazide, Captopril)
Trial: 15595229
Drug: Topical ketoprofen
RxNorm normalized name: ketoprofen Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ketoprofen 20% in a poloxamer-lecithin organogel (PLO)
Trial: 15595229
Drug: Oral 50-mg
RxNorm normalized name: hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral 50-mg ketoprofen capsule
Trial: 10802278
Drug: Nestorone alone
RxNorm normalized name: Nestorone
DrugBank: Segesterone acetate (DB14583)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nestorone alone (50, 75, 100 µg daily over 6 months)
Trial: 10802278
Drug: ethinyl estradiol:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ethinyl estradiol: Nestorone (30:100 and 15:150 µg daily over 6 months)
Trial: 10802278
Drug: ethinylestradiol:norethindrone acetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ethinylestradiol:norethindrone acetate (20:1000 and 15:1000 µg daily over 4 months)
Trial: 10802278
Drug: ethinyl estradiol:norethindrone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ethinyl estradiol:norethindrone acetate (20:1000 µg daily over 12 months)
Trial: 2062620
Drug: HbOC vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HbOC vaccine (3-dose regimen, first dose between 6 weeks and 6 months, minimum interval of 1 month between doses, third dose by 1 year of age)
Trial: 2062620
Drug: HbOC vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HbOC vaccine (3-dose regimen)
Trial: 2062620
Drug: HbOC vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HbOC vaccine (1 dose)
Trial: 8352217
Drug: HbOC vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HbOC vaccine